• Tue news: Where do Harris and Trump stand on health policy? Medtronic renal denervation coverage. Canada less likely to have drug shortages? Wall Street wants CVS execution plan. Nektar manufacturing facility sale. See more on our front page

Peter Kim compensation

Quote
Anonymous said:
MRL is actually in pretty good shape under Peter Kim's leadership. There are compounds in the pipeline, excellent researchers and strong leadership. There have been a few setbacks lately, but nothing to worry about. The company will be on its feet soon.
Click to expand...

You asshole-Merck's 1Q09 profits are down over 50%. You still think Merck is in good shape and there is nothing to worry about??? Maybe your thinking will change when they kick you out.
 




Anonymous said:
This guy and Kathleen Metters are complete idiots. They restructured MRL to have multiple franchises at each site to be in line with the one Merck concept, only reverse it back two or three years later. This time, worse, they moved franchises to sites with no expertise at all, for example, infectious diseases to Merck Frosst and inflammation to Boston. What a waste!
Click to expand...

Doing this will permit the closing of Frosst within 2 years. KM already has moved her "favorites" out of there. This will move ID to Scherings labs in NJ and save costs. She still calls herself world-wide head of basic research. Should be renamed to US head.
 




Anonymous said:
Do you think anyone in the upper management or the board reads this? If not, we should forward this thread to their attention.
Click to expand...

No - upper management is too busy collecting the big pay checks and not really caring what you or I think - remember, we are the low level employees that can be discarded at will especially if the performance is not there, unlike upper management that promotes themselves and gives themselves raises as their performance continues to deteriorate - it just is the way it is...
 








The competitions must be laughing with this guy in charge of MRL. Remember he did not even know how to ask questions when he went to site reviews. His favorite question was what was known about the knockout mouse. Maybe he has made some progress but I doubt it.
 
















Come on. Give this poor guy a couple of more years. Maybe all he needs is more time! To completely ruin not only the drug but also people pipeline. Interestingly, he does not talk about people pipeline any more.
 








The next critical time for him is the merger. He will buy some more time if he can survive it. Then, he will have to face a new CEO. But he will rake in a few more millions by then.
 








































Top Bottom
Back
Quote